New Alzheimer’s drug aducanumab: what we know so far – and why more research is still needed
(Version anglaise seulement)
par Eleftheria Kodosaki, Research Associate in Neuroimmunology, Cardiff University
Aurora Veteleanu, PhD Candidate, Neuroscience, Cardiff University
The first drug targeting Alzheimer's disease has been approved in 20 years – but its approval isn't based on substantial evidence.
Lire l'article complet
© La Conversation
-
vendredi 11 juin 2021
